KalVista reports Q1 FY2024 net loss $25.3M; KONFIDENT phase 3 enrollment achieved

KalVista Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.74

Net loss $25.3M ($0.74/share) vs $23.0M ($0.94/share) in prior-year quarter.
Cash, equivalents and marketable securities $123.3M vs $149.4M as of April 30, 2023.
Phase 3 KONFIDENT trial for sebetralstat hit enrollment target of 114 patients; data readout on track for Q4 2023.
NDA submission planned for H1 2024; Nicole Sweeny appointed Chief Commercial Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

KalVista Pharmaceuticals, Inc. reported the first fiscal quarter ended July 31, 2023 results: net income $25.3 million, or $(0.74) per weighted average basic and diluted share, EPS $(0.74) per weighted average basic and diluted share.

Period: the first fiscal quarter ended July 31, 2023
Net income: $25.3 million, or $(0.74) per weighted average basic and diluted share
EPS: $(0.74) per weighted average basic and diluted share
Result: reported results

Exact text from the filing

KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update

View on SEC.gov

Browse all earnings releases →

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-047036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.